A $2.1 billion funding round fuels Isomorphic Labs as it scales its Drug Design Engine. The Google DeepMind spinoff partnered with Novartis and Eli Lilly to identify hidden drug targets. This technical approach leverages protein structure prediction to shorten discovery cycles. Practitioners can now target previously undruggable proteins with higher precision.